FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

M. C. Genovese; J. S. Smolen; T. Takeuchi; G. R. Burmester; W. Deberdt; D. Schlichting; H. Song; D. Mo; C. Walls; K. Winthrop

doi:10.1136/annrheumdis-2020-eular.1723

Article info

Scientific Abstracts

Poster Presentations

Friday, 05 June 2020

Rheumatoid arthritis - non biologic treatment and small molecules

FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

Authors

M. C. Genovese Stanford University, Division of Immunology and Rheumatology, Palo Alto, CA, United States of America PubMed articles Google scholar articles
J. S. Smolen Medical University of Vienna, Division of Rheumatology, Department of Medicine, Vienna, Austria PubMed articles Google scholar articles
T. Takeuchi Keio University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan PubMed articles Google scholar articles
G. R. Burmester Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany PubMed articles Google scholar articles
W. Deberdt Eli Lilly and Company, Indianapolis, IN, United States of America PubMed articles Google scholar articles
D. Schlichting Eli Lilly and Company, Indianapolis, IN, United States of America PubMed articles Google scholar articles
H. Song Syneos Health, Morrisville, NC, United States of America PubMed articles Google scholar articles
D. Mo Eli Lilly and Company, Indianapolis, IN, United States of America PubMed articles Google scholar articles
C. Walls Eli Lilly and Company, Indianapolis, IN, United States of America PubMed articles Google scholar articles
K. Winthrop Oregon Health Sciences University, Portland, OR, United States of America PubMed articles Google scholar articles

Citation

Genovese MC, Smolen JS, Takeuchi T, et al

FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

Annals of the Rheumatic Diseases 2020;79:642-643.

Publication history

First published June 2, 2020.

Online issue publication

June 02, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password